Johnson & Johnson to Pay $1.25 Billion to Acquire Investigational Treatment for Atopic Dermatitis
- May 31, 2024
Johnson & Johnson (J&J) will pay $1.2 billion to acquire from Numab Therapeutics the global rights to an investigational treatment for atopic dermatitis, according to a May 28 press release.
ARTICLE TAGS
You must be logged in to access this content.